Amitriptyline
Amitriptyline is metabolized by the hepatic cytochrome P450 isozymes CYP2D6, CYP2C19, CYP3A4, GYP1A2 and CYP2C9. CBD inhibits these enzymes; concomitant use of CBD with amitriptyline may increase the risk of adverse effects e.g. anticholinergic syndrome, drowsiness, and QT interval prolongation, Concomitant use of cannabidiol with drugs with sedative and anaesthetic properties, e.g. amitriptyline, gabapentin, pregabalin, may cause additive therapeutic and adverse effects
Celecoxib
Celecoxib is metabolized in the liver predominantly by CYP2C9, but CYP3A4 also plays a role (<25 %). Cannabidiol is known in vitro to inhibit both CYP2C9 and CYP3A4. This interaction has yet to reported in humans; however, until more is known, caution is advised because concomitant use could increase serum levels and the risk of adverse effects
Citalopram
Citalopram is metabolized in the liver by CYP2C19 (-38 %), CYP3A4 (-31 %) and CYP2D6 (-31 %). Cannabidiol inhibits both CYP2C19 and CYP3A4 in vitro, but this interaction has yet to be reported in humans. Inhibition of more than one enzyme can result in significant increases in serum levels and the risk of adverse effects Etoricoxib See Celecoxib
Fluoxetine
Fluoxetine is metabolized in the liver by CYP2D6 and CYP2C9. Cannabidiol inhibits CYP2D6 and CYP2C9 in vitro. This interaction has yet to be reported in humans; however, until more is known caution is advised because concomitant use could increase serum levels and the risk of adverse effects Gabapentin See Amitriptyline
Hydrocortisone Hydrocortisone and prednisolone are both metabolized by cytochrome CYP3A, and cannabidiol has been shown to inhibit CYP3A. Concomitant use may, therefore, decrease glucocorticoid clearance and increase the risk of systemic CS side effects. This combination should be avoided unless the benefits outweigh the risk, in which case patients should be monitored for systemic CS side effects, and if necessary the dose of glucocorticoids should be decreased
Mirtazapine
Mirtazapine is metabolized by cytochrome CYP1A2, CYP2D6 and CYP3A4. In vitro research shows that cannabidiol inhibits cytochromes CYP1A2, CYP2D6 and CYP3A4. These interactions have yet to be reported in humans; however, until more is known, caution is advised because concomitant use could potentially increase serum levels and the risk of adverse effects Naproxen Naproxen is metabolized in the liver by CYP2C9, and cannabidiol is known in vitro to inhibit CYP2C9. This may theoretically increase the risk of adverse effects
Paroxetine
Paroxetine is converted to inactive metabolites by cytochrome CYP2D6. In vitro research has shown cannabidiol to inhibit CYP2D6. This interaction has yet to be reported in humans; however, until more is known, caution is advised because concomitant use could potentially increase serum levels and the risk of adverse effects
Prednisolone See Hydrocortisone
Pregabalin See Amitriptyline
Sertraline
Sertraline is metabolized by CYP3A4. In vitro research has shown cannabidiol to inhibit CYP3A4. This interaction has yet to be reported in humans; however, until more is known, use with caution because concomitant use could potentially increase serum levels and the risk of adverse effects Tofacitinib Tofacitinib is metabolized in the liver, predominantly by CYP3A4, with a smaller contribution from CYP2C19. Cannabidiol is known in vitro to inhibit these cytochromes. Though this interaction has yet to be reported in humans, concomitant use may therefore increase serum exposure, and a dose reduction to 5 mg once daily is advised
Tramadol
In vitro research shows that cannabidiol inhibits CYP2D6, which is involved in the biotransformation of tramadol; its inhibition may therefore affect the plasma concentration of tramadol or its active metabolite 
